(9ci)-1-(1-甲基乙基)-1H-苯并咪唑-2-甲醇 | 305347-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-1-(1-甲基乙基)-1H-苯并咪唑-2-甲醇
• 中文别名: (1-丙-2-基苯并咪唑-2-基)甲醇；(1-异丙基-1H-苯并咪唑-2-基)甲醇；(1-异丙基-2-苯并咪唑基)甲醇；(1-异丙基苯并咪唑-2-基)甲醇；(1-异丙基-1H-苯并咪唑基-2-基)-甲醇
• 英文名称: (1-isopropyl-1H-benzo[d]imidazole-2-yl)methanol
• 英文别名: (1-isopropyl-1H-benzo[d]imidazol-2-yl)methanol；[1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol；(1-Isopropyl-1H-benzimidazol-2-yl)methanol；(1-propan-2-ylbenzimidazol-2-yl)methanol
• CAS: 305347-19-7
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD01942611
• 分子量: 190.245
• InChiKey: IJXQWUGHKOHMKR-UHFFFAOYSA-N

物化性质

• 沸点：
  352.2±25.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (9ci)-1-(1-甲基乙基)-1H-苯并咪唑-2-甲醇 在 三溴化磷 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-(bromomethyl)-1-(propan-2-yl)-1H-benzimidazole
  参考文献：
  名称：

  [EN] METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS
  [FR] MÉTHYLSULFANYLPYRIMIDINES UTILES EN TANT QU'AGENTS ANTI-INFLAMMATOIRES, ANALGÉSIQUES, ET ANTI-ÉPILEPTIQUES

  摘要：

  公开号：

  WO2010132999A8
• 作为产物：
  描述：

  邻苯二胺 在 盐酸 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (9ci)-1-(1-甲基乙基)-1H-苯并咪唑-2-甲醇
  参考文献：
  名称：

  新型苯并咪唑-噻唑烷二酮杂化物作为潜在的细胞毒性和凋亡诱导剂的合成及生物学评价

  摘要：

  已经合成了一系列新的苯并咪唑-噻唑烷二酮杂化物，并评估了它们对选定的人类前列腺癌细胞系（PC-3和DU-145），乳腺（MDA-MB-231），肺（A549）和正常的乳腺上皮细胞（MCF10A）。在测试的化合物中，11p对A549肺癌细胞系表现出有希望的细胞毒性，IC 50值为11.46±1.46μM，对正常的MCF10A细胞没有明显的毒性。肺癌细胞（A549）已被用于了解化合物11p抑制细胞生长和诱导细胞凋亡的机制。用11p处理A549细胞表现出典型的凋亡形态，如细胞萎缩，染色质浓缩和马蹄形核形成。流式细胞仪分析显示细胞周期阻滞的G2 / M期呈剂量依赖性。初步的机理研究表明，细胞迁移受到F-肌动蛋白蛋白破坏的抑制。cr啶橙-溴化乙锭（AO-EB），DAPI，膜联蛋白V-FITC /碘化丙啶，若丹明123和MitoSOX分析表明，化合物11p诱导了A549细胞凋亡。

  DOI：

  10.1016/j.ejmech.2016.08.029

文献信息

• Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents
  作者：Pankaj Sharma、T. Srinivasa Reddy、Dinesh Thummuri、Kishna Ram Senwar、Niggula Praveen Kumar、V.G.M. Naidu、Suresh K. Bhargava、Nagula Shankaraiah

  DOI：10.1016/j.ejmech.2016.08.029

  日期：2016.11

  human cancer cell lines of prostate (PC-3 and DU-145), breast (MDA-MB-231), lung (A549) and a normal breast epithelial cells (MCF10A). Among the tested compounds, 11p exhibited promising cytotoxicity with IC50 value of 11.46 ± 1.46 μM on A549 lung cancer cell line and did not show significant toxicity on normal MCF10A cells. Lung cancer cells (A549) have been used to know the mechanism of cell growth

  已经合成了一系列新的苯并咪唑-噻唑烷二酮杂化物，并评估了它们对选定的人类前列腺癌细胞系（PC-3和DU-145），乳腺（MDA-MB-231），肺（A549）和正常的乳腺上皮细胞（MCF10A）。在测试的化合物中，11p对A549肺癌细胞系表现出有希望的细胞毒性，IC 50值为11.46±1.46μM，对正常的MCF10A细胞没有明显的毒性。肺癌细胞（A549）已被用于了解化合物11p抑制细胞生长和诱导细胞凋亡的机制。用11p处理A549细胞表现出典型的凋亡形态，如细胞萎缩，染色质浓缩和马蹄形核形成。流式细胞仪分析显示细胞周期阻滞的G2 / M期呈剂量依赖性。初步的机理研究表明，细胞迁移受到F-肌动蛋白蛋白破坏的抑制。cr啶橙-溴化乙锭（AO-EB），DAPI，膜联蛋白V-FITC /碘化丙啶，若丹明123和MitoSOX分析表明，化合物11p诱导了A549细胞凋亡。
• BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS
  申请人：Verhoest R, Patrick

  公开号：US20070155779A1

  公开（公告）日：2007-07-05

  The invention pertains to bicyclic heteroaryl compounds that serve as effective phosphodiesterase (PDE) inhibitors The invention also relates to compounds which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

  这项发明涉及用作有效磷酸二酯酶（PDE）抑制剂的双环杂环芳基化合物。该发明还涉及选择性抑制PDE-10的化合物。此外，该发明还涉及制备这种化合物的中间体；包含这种化合物的药物组合物；以及将这种化合物用于治疗某些中枢神经系统（CNS）或其他疾病的方法。该发明还涉及治疗神经退行性和精神障碍的方法，例如精神病和包括认知缺陷作为症状的疾病。
• PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS
  申请人：Université Laval

  公开号：US20150225423A1

  公开（公告）日：2015-08-13

  The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

  本发明涉及具有式(Ia)和(Ib)的化合物(例如，任何公式((Ia-2)-(Ia-21))的化合物，包括其他互变异构体、立体异构体、E/Z立体异构体、前药、药学上可接受的盐及其组合物。本发明还涉及通过给患者施用式(Ia)或(Ib)的化合物的有效量来治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法。本发明还涉及一种治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法，包括向需要的患者施用式(IIa)或(IIb)的化合物的有效量(例如，任何公式((IIa-2)-(IIa-6))的化合物)。本文所描述的化合物(例如，公式(Ia)、(Ib)、(IIa)或(IIb)的化合物)也可用作抗惊厥剂。
• New ( E )-1-alkyl-1 H -benzo[ d ]imidazol-2-yl)methylene)indolin-2-ones: Synthesis, in vitro cytotoxicity evaluation and apoptosis inducing studies
  作者：Pankaj Sharma、Dinesh Thummuri、T. Srinivasa Reddy、Kishna Ram Senwar、V.G.M. Naidu、Gannoju Srinivasulu、Suresh K. Bharghava、Nagula Shankaraiah

  DOI：10.1016/j.ejmech.2016.07.019

  日期：2016.10

  A new series of (E)-benzo[d]imidazol-2-yl)methylene)indolin-2-one derivatives has been synthesized and evaluated for their in vitro cytotoxic activity against a panel of selected human cancer cell lines of prostate (PC-3 and DU-145) and breast (BT-549, MDA-MB-231, MCF-7, 4T1), non-small lung (A549) and gastric (HGC) cancer cells along with normal breast epithelial cells (MCF10A). Among the tested compounds, 81 showed significant cytotoxic activity against MDA-MB-231 and 4T1 cancer cells with IC50 values of 3.26 +/- 0.24 mu M and 5.96 +/- 0.67 mu M respectively. The compounds 8f, 8i, 8l and 8o were also screened on normal human breast epithelial cells (MCF10A) and found to be safer with lesser cytotoxicity. The treatment of MDA-MB-231 cells with 81 led to inhibition of cell migration ability through disruption of F-actin protein assembly. The flow-cytometry analysis reveals that the cells arrested in G0/G1 phase of the cell cycle. Further, the compound 81 induced apoptosis of MDA-MB-231 cells was characterized by different staining techniques such as Acridine Orange/Ethidium Bromide (AO/EB), DAPI, annexin V-FITC/PI, Rhodamine-123 and MitoSOX red assay. Western blot studies demonstrated that the compound 81 treatment led to activation of caspase-3, increased expression of cleaved PARP, increased expression of pro-apoptotic Bax and decreased expression of anti-apoptotic Bcl-2 in MDA-MB-231 cancer cells. (C) 2016 Elsevier Masson SAS. All rights reserved.
• Structure–Activity Relationship and Pharmacokinetic Studies of 1,5-Diheteroarylpenta-1,4-dien-3-ones: A Class of Promising Curcumin-Based Anticancer Agents
  作者：Rubing Wang、Chengsheng Chen、Xiaojie Zhang、Changde Zhang、Qiu Zhong、Guanglin Chen、Qiang Zhang、Shilong Zheng、Guangdi Wang、Qiao-Hong Chen

  DOI：10.1021/acs.jmedchem.5b00470

  日期：2015.6.11

  Forty-three 1,5-diheteroaryl-1,4-pentadien-3-ones were designed as potential curcumin mimics, structurally featuring a central five-carbon dienone linker and two identical nitrogen-containing aromatic rings. They were synthesized using a Horner-Wadsworth-Emmons reaction as the critical step and evaluated for their cytotoxicity and antiproliferative activities toward both androgen-insensitive and androgen-sensitive prostate cancer cell lines and an aggressive cervical cancer cell line. Most of the synthesized compounds showed distinctly better in vitro potency than curcumin in the four cancer cell lines. The structure-activity data acquired from the study validated (1E,4E)-1,5-dihereroaryl-1,4-pentadien-3-ones as an excellent scaffold for in-depth development for clinical treatment of prostate and cervical cancers. 1-Alkyl-1H-imidazol-2-yl, ortho pyridyl, 1-alkyl-1H-benzo[d]imidazole-2-yl, 4-bromo-1-methyl-1H-pyrazol-3-yl, thiazol-2-yl, and 2-methyl-4-(trifluoromethyl)thiazol-5-yl were identified as optimal heteroaromatic rings for the promising in vitro potency. (1E,4E)-1,5-Bis(2-methyl-4-(trifluoromethyl)thiazol-5-yl)penta-1,4-dien-3-one, featuring thiazole rings and trifluoromethyl groups, was established as the optimal lead compound because of its good in vitro potency and attractive in vivo pharmacokinetic profiles.